Literature DB >> 12636982

Does short-course antibiotic therapy better meet patient expectations?

B Perez-Gorricho1, M Ripoll.   

Abstract

A pan-European market research study of 3254 patients designed to determine patient attitudes, expectations and behaviour to antibiotic management of mild-moderate RTIs, identified three key drivers of perceived antibiotic efficacy: length of antibiotic course, time to onset of symptom relief and time to complete resolution of symptoms. Azithromycin was selected as "drug therapy of shortest dosage schedule" for common outpatient infections. The results demonstrate that once-daily, short-course treatment is perceived to be significantly more effective than longer antibiotic courses and thus, better meets patient expectations of therapy. This perception of efficacy with short-course therapy also correlates with overall satisfaction with management by the physician and compliance with therapy. These findings have important implications for the way physicians manage patients with mild-moderate RTIs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636982     DOI: 10.1016/s0924-8579(02)00360-6

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin.

Authors:  Richa Chandra; Ping Liu; Jeanne D Breen; Jeannine Fisher; Charles Xie; Robert LaBadie; Rebecca J Benner; Lisa J Benincosa; Amarnath Sharma
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Fluoroquinolone therapy for uncomplicated skin and skin structure infections : a retrospective database comparison of treatment duration, failures and charges.

Authors:  Karen N Keating; Howard Friedman; Eleanor M Perfetto
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

3.  Randomized, Controlled, Crossover trial of Prevention of Clindamycin-Induced Gastrointestinal Signs Using a Synbiotic in Healthy Research Cats.

Authors:  J E Stokes; J M Price; J C Whittemore
Journal:  J Vet Intern Med       Date:  2017-07-29       Impact factor: 3.333

Review 4.  Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

Authors:  Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

5.  Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].

Authors:  Oguz Karabay; Irfan Sencan; Derya Kayas; Idris Sahin
Journal:  BMC Infect Dis       Date:  2004-06-23       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.